Geron Corporation

Healthcare · Biotechnology · United States

Last price 0.9462 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 607.91M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clini...